Up 200% in 6 months, guess which ASX All Ords stock just hit another all-time high

This All Ords stock has made its investors very rich in recent months…

| More on:
Lab worker puts hands in the air and dances around

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One ASX All Ordinaries Index (ASX: XAO) stock has returned more than 200% to its investors over the past six months alone. Today, it celebrated a second feat by hitting another new all-time high.

Which ASX All Ords company? That would be Clarity Pharmaceuticals Ltd (ASX: CU6). Yes, it was only in early November last year that Clarity shares were trading at $1.06 each. Today, those same shares will set an investor back $3.27.

As mentioned, this Thursday also saw Clarity hit a new record high. Just after the market opened this morning, the All Ords pharmaceutical stock hit $3.31, its new all-time record.

Why has this ASX All Ords stock just hit a new record high?

Here at the Motley Fool, we've been tracking Clarity's rising star over most of the year. Back in January, my Fool colleague analysed Frazis Capital portfolio manager Michael Frazis's view on the company.

Frazis presciently called Clarity "the most exciting company I've come across in Australia lately", thanks to the favourable data surrounding its copper therapy treatment for late-stage prostate cancer.

Frazis also argued that the company remained vastly undervalued compared to its potential:

If their data continues to hold, this is still early days, and it remains a fraction of the value of recent acquisitions in the space with early stage data.

In March, we also discussed ASX broker Bell Potter's optimistic view on Clarity Pharmaceuticals. Bell Potter posited similar sentiments to Frazis, noting Clarity's prostate cancer patient's having "apparently with no disease progression, many months after commencing treatment".

At the time, Bell Potter gave the All Ords stock a 'speculative buy' rating alongside a share price target of $3.25. That target has certainly aged well.

It was only earlier this week that Clarity revealed its first patient to be dosed with two cycles of its treatment achieved "a complete response", with "undetectable levels of prostate specific antigen (PSA) for almost 6 months".

Much of Clarity's share price gains have come since this positive announcement. Since Monday this week, this ASX All Ords stock has gained a whopping 26.4%. Let's see where this exciting company is headed next.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »